It's been quite a week for little Sprout Pharmaceuticals.
On Tuesday, the 34-employee, closely held North Carolina company won approval of the first drug to treat female sexual dysfunction in the U.S. after weathering two previous rejections.
Thursday, it got acquired for a cool $1 billion by drug giant Valeant after what Valeant CEO Mike Pearson says were just three weeks of discussions.
As the smoke clears for Sprout and its drug, Addyi, should we expect to see feminine versions of those classic Viagra and Cialis ads?
Probably not, or at least not any time soon.